Do analysts rate CNSP or PTPI?

CNS Pharmaceuticals currently has a consensus target price of $20.00, suggesting a potential upside of 302.82%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CNSP or PTPI more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% Petros Pharmaceuticals N/A -78.22% -23.50%

Do analysts recommend PTPI or VRAX?

Virax Biolabs Group has a consensus price target of $1.00, suggesting a potential upside of 446.45%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than Petros Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, PTPI or VRAX?

Virax Biolabs Group has lower revenue, but higher earnings than Petros Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Petros Pharmaceuticals $5.11M 0.04 -$8.16M -$1.64 N/A Virax Biolabs Group $2.99K 266.10 -$6.06M N/A N/A

Is PTPI or VRAX more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% Virax Biolabs Group N/A N/A N/A

Is PTPI or WINT more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat Windtree Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% Windtree Therapeutics N/A -207.34% -50.19%

Do analysts recommend PTPI or CARM?

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 19,507.84%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Petros Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is PTPI or HEPA more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% Hepion Pharmaceuticals N/A -812.56% -207.31%

Petros Pharmaceuticals (PTPI) Competitors

$0.0071 +0.00 (+1.43%)

As of 11:50 AM Eastern

Compare

PTPI vs. CNSP, VRAX, WINT, CARM, and HEPA

Should you buy Petros Pharmaceuticals stock or one of its competitors? MarketBeat compares Petros Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Petros Pharmaceuticals include CNS Pharmaceuticals (CNSP), Virax Biolabs Group (VRAX), Windtree Therapeutics (WINT), Carisma Therapeutics (CARM), and Hepion Pharmaceuticals (HEPA). These companies are all part of the "pharmaceutical products" industry.

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

CNS Pharmaceuticals currently has a consensus target price of $20.00, suggesting a potential upside of 302.82%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

CNS Pharmaceuticals has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market.

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 0.0% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

In the previous week, CNS Pharmaceuticals had 3 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 0 mentions for Petros Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.41 beat Petros Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Neutral
Petros Pharmaceuticals	Neutral

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A

Summary

CNS Pharmaceuticals and Petros Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Virax Biolabs Group?

Petros Pharmaceuticals (NASDAQ:PTPI) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

In the previous week, Virax Biolabs Group had 2 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 2 mentions for Virax Biolabs Group and 0 mentions for Petros Pharmaceuticals. Virax Biolabs Group's average media sentiment score of 0.43 beat Petros Pharmaceuticals' score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Virax Biolabs Group	Neutral

Virax Biolabs Group's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Virax Biolabs Group	N/A	N/A	N/A

Petros Pharmaceuticals has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

Virax Biolabs Group has a consensus price target of $1.00, suggesting a potential upside of 446.45%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Virax Biolabs Group has lower revenue, but higher earnings than Petros Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A
Virax Biolabs Group	$2.99K	266.10	-$6.06M	N/A	N/A

Summary

Virax Biolabs Group beats Petros Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Windtree Therapeutics?

Petros Pharmaceuticals (NASDAQ:PTPI) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Petros Pharmaceuticals has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

Windtree Therapeutics has lower revenue, but higher earnings than Petros Pharmaceuticals. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A
Windtree Therapeutics	N/A	N/A	-$1.79M	-$8.77	N/A

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Windtree Therapeutics'average media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Windtree Therapeutics	Neutral

Petros Pharmaceuticals' return on equity of -78.22% beat Windtree Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Windtree Therapeutics	N/A	-207.34%	-50.19%

Summary

Petros Pharmaceuticals beats Windtree Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Carisma Therapeutics?

Petros Pharmaceuticals (NASDAQ:PTPI) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Petros Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Carisma Therapeutics	-254.28%	N/A	-192.17%

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Carisma Therapeutics	Neutral

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 19,507.84%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Petros Pharmaceuticals has higher earnings, but lower revenue than Carisma Therapeutics. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A
Carisma Therapeutics	$10.77M	0.02	-$60.48M	$0.73	0.01

Petros Pharmaceuticals has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Carisma Therapeutics beats Petros Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Hepion Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Hepion Pharmaceuticals	Neutral

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Petros Pharmaceuticals' return on equity of -78.22% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Petros Pharmaceuticals has higher revenue and earnings than Hepion Pharmaceuticals. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

Petros Pharmaceuticals has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Summary

Petros Pharmaceuticals beats Hepion Pharmaceuticals on 8 of the 9 factors compared between the two stocks.

Get Petros Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTPI vs. The Competition

Export

Metric	Petros Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$221K	$970.92M	$6.50B	$12.37B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	0.00	1.47	24.01	24.71
Price / Sales	0.04	127.72	540.55	165.59
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	0.00	8.02	10.55	6.85
Net Income	-$8.16M	-$4.88M	$3.56B	$337.45M
7 Day Performance	N/A	4.75%	1.54%	2.70%
1 Month Performance	N/A	4.52%	2.48%	4.60%
1 Year Performance	N/A	47.58%	26.49%	32.81%

Petros Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTPI Petros Pharmaceuticals	N/A	$0.01 +1.4%	N/A	-77.4%	$221K	$5.11M	N/A	20	Gap Up
CNSP CNS Pharmaceuticals	3.0072 of 5 stars	$4.61 +0.4%	$20.00 +333.8%	-49.5%	$6.71M	N/A	N/A	5	Short Interest Increase
VRAX Virax Biolabs Group	2.7537 of 5 stars	$0.18 -6.0%	$1.00 +465.0%	-79.2%	$820K	$10K	N/A	5	Short Interest Increase
WINT Windtree Therapeutics	N/A	$0.02 -7.5%	N/A	-97.0%	$720K	N/A	N/A	30	Gap Up
CARM Carisma Therapeutics	2.4926 of 5 stars	$0.02 +931.3%	$1.00 +5,960.6%	-98.6%	$690K	$10.77M	0.02	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTPI) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Petros Pharmaceuticals (PTPI) Competitors

PTPI vs. CNSP, VRAX, WINT, CARM, and HEPA

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Summary

How does Petros Pharmaceuticals compare to Virax Biolabs Group?

Summary

How does Petros Pharmaceuticals compare to Windtree Therapeutics?

Summary

How does Petros Pharmaceuticals compare to Carisma Therapeutics?

Summary

How does Petros Pharmaceuticals compare to Hepion Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTPI vs. The Competition

Petros Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Petros Pharmaceuticals (PTPI) Competitors

PTPI vs. CNSP, VRAX, WINT, CARM, and HEPA

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Do analysts rate CNSP or PTPI?

Which has more volatility and risk, CNSP or PTPI?

Do insiders & institutionals believe in CNSP or PTPI?

Is CNSP or PTPI more profitable?

Does the media prefer CNSP or PTPI?

Which has higher valuation and earnings, CNSP or PTPI?

Summary

How does Petros Pharmaceuticals compare to Virax Biolabs Group?

Does the media refer more to PTPI or VRAX?

Is PTPI or VRAX more profitable?

Which has more risk & volatility, PTPI or VRAX?

Do analysts recommend PTPI or VRAX?

Do insiders and institutionals have more ownership in PTPI or VRAX?

Which has higher valuation & earnings, PTPI or VRAX?

Summary

How does Petros Pharmaceuticals compare to Windtree Therapeutics?

Which has more volatility and risk, PTPI or WINT?

Which has higher valuation & earnings, PTPI or WINT?

Do insiders and institutionals have more ownership in PTPI or WINT?

Does the media refer more to PTPI or WINT?

Is PTPI or WINT more profitable?

Summary

How does Petros Pharmaceuticals compare to Carisma Therapeutics?

Is PTPI or CARM more profitable?

Does the media favor PTPI or CARM?

Do analysts recommend PTPI or CARM?

Which has stronger earnings and valuation, PTPI or CARM?

Which has more volatility & risk, PTPI or CARM?

Do insiders and institutionals hold more shares of PTPI or CARM?

Summary

How does Petros Pharmaceuticals compare to Hepion Pharmaceuticals?

Does the media prefer PTPI or HEPA?

Do institutionals & insiders have more ownership in PTPI or HEPA?

Is PTPI or HEPA more profitable?

Which has higher valuation and earnings, PTPI or HEPA?

Which has more volatility & risk, PTPI or HEPA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTPI vs. The Competition

Petros Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools